Newsmeme!
Discover News you didn't know existed
Allergic Rhinitis
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Clinical Trials Update: July 2, 2009
Published July 2, 2009, 9:45 am, Forbes
If your child (boys aged five to eight and girls aged five to seven) has had allergy symptoms for at least one year, he or she may qualify for this study.
Sepracor Provides Update On Clinical Trials For SEP-225289 And LUNESTA(R) Pediatrics
Published July 2, 2009, 9:09 am, Medical News Today
Sepracor Inc. (Nasdaq: SEPR) announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive Disorder, including patients with melancholic and atypical features.
Clinical Trials Update: July 2, 2009
Published July 2, 2009, 9:04 am, HealthDay via Yahoo! News
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch and ClinicalConnection.com:
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data For AM211, A Novel Product Candidate For The ...
Published July 1, 2009, 4:10 am, Medical News Today
Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor. The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211.
Lupin acquires world-wide rights of nasal steroid
Published June 30, 2009, 8:43 am, The Times of India
Pharma major Lupin on Tuesday said that it has acquired the world-wide rights for the intra-nasal steroid (INS) product AllerNaze nasal spray 50 mcg from Collegium Pharmaceutical Inc.
Lupin Expands Branded Play
Published June 30, 2009, 8:01 am, PR Newswire via Yahoo! Finance
AllerNaze
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the ...
Published June 30, 2009, 7:18 am, redOrbit
Results Demonstrate Positive Proof of Mechanism SAN DIEGO, June 30 /PRNewswire/ -- Amira Pharmaceuticals, Inc.
Scientists Receive £4.3 Million For Pioneering Asthma And Allergy-Prevention Research, London
Published June 30, 2009, 6:08 am, Medical News Today
Researchers at St George's, University of London have been awarded £4.3 million by the Wellcome Trust for the development of a unique new class of drugs to target the root cause of asthma and allergies. The new Allergen Delivery Inhibitors may be superior to existing medicines, which mainly relieve symptoms.
Lupin acquires global rights for nasal spray AllerNaze
Published June 30, 2009, 5:14 am, The Hindu
MUMBAI: Pharma firm Lupin on Tuesday said it has acquired the worldwide rights for nasal spray AllerNaze from Collegium Pharmaceutical for an undisclosed amount.
Collegium Pharmaceutical Announces the Sale of AllerNaze to Lupin
Published June 30, 2009, 5:00 am, Business Wire via Yahoo! Finance
CUMBERLAND, R.I.----Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that Lupin has acquired all worldwide rights to AllerNaze™ Nasal Spray, 50 mcg.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |